Skip to Main Content
Contribute Try STAT+ Today

In an unusual move, a private equity firm is soliciting investors to help create a chain of cancer centers that would focus on providing experimental medicines that are available under the controversial Right to Try law that went into effect two years ago.

Earlier this month, Vivaris Capital began touting United Cancer Centers, which is described as the “first institutional health care system” in the U.S. to offer “integrative cancer care.” A big selling point for patients will be helping them obtain medicines under the Right to Try law, which largely cuts the Food and Drug Administration out of the process for determining when dying patients can access experimental drugs being studied in clinical trials.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Is anyone keeping track of whether RTT has prolonged anyone’s life beyond standard treatment ?

Comments are closed.